AA
IMUX icon

Addison Advisors’s Immunic IMUX Stock Holding History

Addison Advisors’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-520
Closed -$2.78K – 988
2025
Q4 		$2.78K Hold
520
– – ﹤0.01% 760
2025
Q3 		$4.58K Hold
520
– – ﹤0.01% 711
2025
Q2 		$3.63K Hold
520
– – ﹤0.01% 728
2025
Q1 		$5.67K Hold
520
– – ﹤0.01% 652
2024
Q4 		$5.2K Buy
+520
New +$6.55K ﹤0.01% 666

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Addison Advisors's IMUX Position: Q1 2026 in Review

Addison Advisors sold out of Immunic (IMUX) in Q1 2026, closing a stake of 520 shares — an estimated $2.78K sold.

Addison Advisors first reported a position in IMUX in Q4 2024 and held it in 5 quarters. The position peaked at $5.67K in Q1 2025. 75 funds tracked by Wall St. Rank hold IMUX as of Q1 2026.

  • Addison Advisors reported no remaining Immunic position as of Q1 2026 after selling out during the quarter.
  • Addison Advisors sold 520 Immunic shares in Q1 2026, an estimated $2.78K.
  • Addison Advisors first reported a position in Immunic in Q4 2024 and held it in 5 quarters.
  • Addison Advisors's Immunic position peaked at $5.67K in Q1 2025.
  • 75 funds tracked by Wall St. Rank held Immunic as of Q1 2026.

Based on Addison Advisors's 13F filing for Q1 2026, filed 8 May 2026.